Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2014
This article has no abstract
Epistemonikos ID: 3752dc65b4d0922898b649eaf9f397412b6d82a0
First added on: Feb 06, 2025